Edition:
United States

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

2.38USD
23 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.38
Open
$2.40
Day's High
$2.64
Day's Low
$2.35
Volume
44,063
Avg. Vol
19,647
52-wk High
$7.15
52-wk Low
$2.00

Select another date:

Mon, Apr 23 2018

BRIEF-Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of Contrave

* PERNIX THERAPEUTICS ANNOUNCES PARTICIPATION IN LEAD BID FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS

BRIEF-Pernix Therapeutics Reports Q4 Loss Per Share $2.78

* PERNIX THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Pernix Announces Patent Litigation Settlement Agreement With Actavis

* PERNIX ANNOUNCES PATENT LITIGATION SETTLEMENT AGREEMENT WITH ACTAVIS CONCERNING ZOHYDRO® ER

BRIEF-Pernix Therapeutics Will Reduce Workforce By 41 Employees

* PERNIX THERAPEUTICS HOLDINGS INC - WILL REDUCE WORKFORCE BY 41 EMPLOYEES; MAJORITY EXPECTED TO BE WITH CO'S SALES FORCE & COMMERCIAL INFRASTRUCTURE

BRIEF-Pernix Therapeutics files for mixed shelf offering of up to $150 mln

* Pernix Therapeutics Holdings files for mixed shelf offering of up to $150 million - SEC filing‍​ Source text: (http://bit.ly/2jg0Ica) Further company coverage:

BRIEF-Pernix Therapeutics posts Q3 revenue of $40.5 mln

* Pernix Therapeutics reports third quarter 2017 financial results

BRIEF-Pernix Therapeutics announces sale of non-core product

* Pernix Therapeutics Holdings Inc - ‍sale of a non-core product Cedax to SI Pharmaceuticals LLC, for $2 million in gross cash proceeds​ Source text for Eikon: Further company coverage:

Select another date: